StockNews.AI
BCYC
StockNews.AI
89 days

Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting

1. Bicycle Therapeutics presents two abstracts on BT8009 at ASCO 2025. 2. BT8009 targets Nectin-4 in metastatic urothelial cancer treatments. 3. The presentations are scheduled for June 2 in Chicago. 4. Advances in Bicycle® molecules are notable in drug development. 5. Company focuses on unique therapeutic solutions for underserved diseases.

4m saved
Insight
Article

FAQ

Why Bullish?

The presentation at ASCO signifies increasing visibility and credibility in oncology. Historically, successful presentations at key conferences often lead to positive market reactions for biotech stocks.

How important is it?

The article discusses significant clinical developments that could influence investor sentiment and expectations. Given BCYC's focus on innovative therapies, this conference is crucial for potential partnerships or increased funding.

Why Short Term?

The immediate upcoming ASCO presentation can drive investor interest and share price fluctuations. Previous ASCO events have shown such impact on biotech stock valuations around presentation dates.

Related Companies

NVTACLVSARKG
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the poster presentation of two abstracts at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago. Poster Presentation Details: Title: Phase 1/2 Duravelo-1 study: Preliminary results of Nectin-4-targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer Poster Session: Genitourinary Cancer—Kidney and Bladder Date and Time: Monday, June 2, at 9 a.m.-12 p.m. CT Abstract Number: 4567 Lead Author: Patrizia Giannatempo, M.D., Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy Title: A phase 2/3 study of Bicycle® Drug Conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC; Duravelo-2) Poster Session: Genitourinary Cancer—Kidney and Bladder Date and Time: Monday, June 2, at 9 a.m.-12 p.m. CT Abstract Number: TPS4619 Lead Author: Yohann Loriot, M.D., Ph.D., Gustave Roussy Institute, University Paris-Saclay, Villejuif, France The posters will be made available in the Publications section of the Bicycle Therapeutics website at the beginning of the poster session. About Bicycle Therapeutics Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Drug Conjugate (BDC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BDC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com.

Related News